News | August 20, 2023
Lupin receives approval from USFDA for Bromfenac Ophthalmic
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Jeet will be a trusted partner in cardiovascular care
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).
CiplaMed 2.0 leverages advanced analytics and automation
Subscribe To Our Newsletter & Stay Updated
